

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) Sheet 1 of 12	<b>Confirmation Number</b>	7706
	<b>Application Number</b>	10/813,965
	<b>Filing Date</b>	March 31, 2004
	<b>First Named Inventor</b>	Robert Falotico
	<b>Group Art Unit</b>	1628
	<b>Examiner Name</b>	Jennifer M. Kim
	<b>Attorney Docket Number</b>	CRD5073USNP

**U.S. PATENT DOCUMENTS**

Exam Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			
		09/948,987		See U.S. Patent 6,764,507		
		3,576,886		Neuworth	04-27-1971	
		3,862,332		Barnhart, et al.	01-21-1975	
		3,929,992		Sehgal, et al.	12-30-1975	
		3,959,078		Guire	05-25-1976	
		4,350,160		Kolesov, et al.	09-21-1982	
		4,366,819		Kaster	01-04-1983	
		4,368,736		Kaster	01-18-1983	
		4,624,257		Berggren, et al.	11-25-1986	
		4,722,906		Guire	02-02-1988	
		4,733,665		Palmaz	03-29-1988	
		4,739,762		Palmaz	04-26-1988	
		4,776,337		Palmaz	10-11-1988	
		4,814,470		Colin, et al.	02-21-1989	
		4,857,653		Colin, et al.	08-15-1989	
		4,917,090		Berggren, et al.	04-17-1990	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov). <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE  STATEMENT BY APPLICANT</b> (use as many sheets as necessary) Sheet 2 of 12	<b>Confirmation Number</b>	7706
	<b>Application Number</b>	10/813,965
	<b>Filing Date</b>	March 31, 2004
	<b>First Named Inventor</b>	Robert Falotico
	<b>Group Art Unit</b>	1628
	<b>Examiner Name</b>	Jennifer M. Kim
	<b>Attorney Docket Number</b>	CRD5073USNP

**U.S. PATENT DOCUMENTS**

Exam Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			
		4,917,091		Berggren, et al.	04-17-1990	
		4,942,184		Haugwitz, et al.	07-17-1990	
		4,984,060		Ohmi, et al.	01-08-1991	
		5,059,699		Kingston, et al.	10-22-1991	
		5,200,534		Rao	04-06-1993	
		5,202,448	A	Carver, et al.	04-13-1993	
		5,229,172	A	Cahalan, et al.	07-20-1993	
		5,229,529	A	Veno, et al.	07-20-1993	
		5,234,447	A	Kaster, et al.	08-10-1993	
		5,248,796	A	Chen, et al.	09-28-1993	
		5,254,580	A	Chen, et al.	10-19-1993	
		5,272,171	A	Ueda, et al.	12-21-1993	
		5,274,137	A	Nicolaou, et al.	12-28-1993	
		5,278,324	A	Kingston	01-11-1994	
		5,279,949	A	Muraleedharan	01-18-1994	
		5,283,253	A	Holton, et al.	02-01-1994	
		5,294,637	A	Chen, et al.	03-15-1994	
		5,294,997	A	Ogura, et al.	03-15-1994	
		5,300,638	A	Farina, et al.	04-05-1994	
		5,308,641	A	Cahalan, et al.	05-03-1994	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov). <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. <sup>6</sup> If possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE                  STATEMENT BY APPLICANT</b> (use as many sheets as necessary) Sheet 3 of 12	<b>Confirmation Number</b>	7706
	<b>Application Number</b>	10/813,965
	<b>Filing Date</b>	March 31, 2004
	<b>First Named Inventor</b>	Robert Falotico
	<b>Group Art Unit</b>	1628
	<b>Examiner Name</b>	Jennifer M. Kim
	<b>Attorney Docket Number</b>	CRD5073USNP

**U.S. PATENT DOCUMENTS**

Exam Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			
		5,339,906	A	Fox, et al.	08-23-1994	
		5,350,800	A	Verhoeven, et al.	09-27-1994	
		5,350,866	A	Holton, et al.	09-27-1994	
		5,352,805	A	Nakata, et al.	10-12-1993	
		5,362,831	A	Mongelli, et al.	11-08-1994	
		5,380,751	A	Chen	01-10-1995	
		5,395,850	A	Roth	03-07-1995	
		5,400,056	A	Klein, et al.	08-08-1995	
		5,411,984		Kingston, et al.	05-02-1995	
		5,412,092		Rey, et al.	05-02-1995	
		5,415,938	A	Cahalan, et al.	05-16-1995	
		5,422,364		Nicolaou	06-06-1995	
		5,516,770	A	Waranis, et al.	05-14-1996	
		5,837,313	A	Ding, et al.	11-17-1998	
		5,891,845	A	Myers	04-06-1999	
		5,924,997		Campbell	07-20-1999	
		6,099,562	A	Ding, et al.	08-08-2000	
		6,120,536	A	Ding, et al.	09-19-2000	
		6,153,252	A	Hossainy, et al.	11-28-2000	
		6,241,762	B1	Shanley	06-05-2001	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov). <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p><b>Substitute for form 1449A/PTO</b></p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p> <p>Sheet 4 of 12</p>	<i>Confirmation Number</i>	7706
	<i>Application Number</i>	10/813,965
	<i>Filing Date</i>	March 31, 2004
	<i>First Named Inventor</i>	Robert Falotico
	<i>Group Art Unit</i>	1628
	<i>Examiner Name</i>	Jennifer M. Kim
	<i>Attorney Docket Number</i>	CRD5073USNP

## U.S. PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov). 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 12

<i>Confirmation Number</i>	7706
<i>Application Number</i>	10/813,965
<i>Filing Date</i>	March 31, 2004
<i>First Named Inventor</i>	Robert Falotico
<i>Group Art Unit</i>	1628
<i>Examiner Name</i>	Jennifer M. Kim
<i>Attorney Docket Number</i>	CRD5073USNP

**FOREIGN PATENT DOCUMENTS**

Exam Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	† <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	KindCode <sup>5</sup>				
		WO	93/10076	A1	University of Mississippi	05-27-1993		
		WO	93/19763	A	American Home Products Corporation	10-14-1993		
		WO	93/23555	A1	Penn State Research Foundation	11-25-1993		
		WO	93/24476	A1	Cover Consolidated, Limited	12-09-1993		
		WO	94/00156	A1	Farmitalia Carlo Erba S.R.L.	01-06-1994		
		WO	94/07876	A1	Rhone-Poulenc Rorer, S.A.	04-14-1994		
		WO	94/07880	A1	Rhone-Poulenc Rorer, S.A.	104-14-1994		
		WO	94/07881	A1	Rhone-Poulenc Rorer, S.A.	04-14-1994		
		WO	94/07882	A1	Rhone-Poulenc Rorer, S.A.	04-14-1994		
		WO	94/20089	A1	Enzon, Inc.	09-15-1994		
		WO	04/026182	A2	Conor Medsystems, Inc.	04-01-2004		
		WO	04/043510	A1	Conor Medsystems, Inc.	05-27-2004		
		WO	04/110302	A2	Conor Medsystems, Inc.	12-23-2004		
		WO	04/011000	A	Wyeth Corporation	02-05-2004		
		EP	0041795	B1	Ayerst, McKenna and Harrison Inc.	12-16-1981		
		EP	0950386	A	Cordis Corporation	10-20-1999		
		EP	590267	B1	Bristol-Myers Squibb Company	07-30-1993		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov). <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 12

Confirmation Number	7706
Application Number	10/813,965
Filing Date	March 31, 2004
First Named Inventor	Robert Falotico
Group Art Unit	1628
Examiner Name	Jennifer M. Kim
Attorney Docket Number	CRD5073USNP

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		<b>AJROLDI, G., et al.</b> "Fluoroelastomers-Dependence of Relaxation Phenomena on Composition", Polymer (1989) Vol. 30. p. 2180-2187	
		<b>ANDERSON, T., et al.</b> "The Effect of Cholesterol-Lowering and Antioxidant Therapy on Endothelium-Dependent Coronary Vasomotion", The New England Journal of Medicine, Vol. 332, No. 8, pp. 488-493 (February 23, 1995)	
		<b>BENEDECK, M., et al.</b> "Smooth Muscle Cell Migration and Matrix Metalloproteinase Expression After Arterial Injury in the Rat", Circulation Research pp. 539-545 (1994)	
		<b>BERK, B., et al.</b> "Pharmacologic Roles of Heparin and Glucocorticoids to Prevent Restenosis After Coronary Angioplasty", J. Am. Coll. Cardio. Vol. 17 (Suppl B); pp. 111B-117B (1991)	
		<b>BEUTLER, E., et al.</b> "Cladribine (2-Chlorodeoxyadenosine)", The Lancet (1992) Vol. 340, pp. 952-956	
		<b>BREHM, B., et al.</b> "β-Blockers of the Third Generation Inhibit Endothelin-1-Liberation, mRNA Production and Proliferation of Human Coronary Smooth Muscle and Endothelial Cells", Journal of Cardiovascular Pharmacology", (2000) Suppl. 1, Vol. 36, pp. S401-S403	
		<b>BREHM, B., et al.</b> "Chronically Elevated Endothelin-1 Concentrations Modulate the β-Adrenergic Receptor System in Vitro and in Vivo", Journal of Cardiovascular Pharmacology (2000) Suppl. 1 Vol. 36, p. S157-S159	
		<b>BURTON, G., et al.</b> "β-Carotene: An Unusual Type of Lipid Antioxidant", Science, Vol. 224 (1984) pp. 569-573	
		<b>CARRERA, C., et al.</b> "Potent Toxicity of 2-Chlorodeoxyadenosine Toward Human Monocytes in Vitro and in Vito", J. Clinical Investigation Vol. 86 pp. 1480-1488 (1990)	
		<b>CARSON, D., et al.</b> "Specific Toxicity of 2-Chlorodeoxyadenosine Toward Resting and Proliferating Human Lymphocytes", Book 62 pp. 737-743 (1983)	
		<b>CHANG, M., et al.</b> "Adenovirus-Mediated Over-Expression of the Cyclin/Cyclin-Dependent Kinase Inhibitor", J. Clinical Investigation, Vol. 96, pp. 2260-2268 (1995)	
		<b>CLOWES, A., et al.</b> "Kinetics of Cellular Proliferation After Arterial Injury, II. Inhibition", Lab. Invest. Vol. 52(6) pp. 611-616 (1985)	
		<b>CLOWES, A., et al.</b> "Kinetics of Cellular Proliferation After Arterial Injury, IV. Heparin", Circulation Research Vol. 58, p. 839-845 (1986)	
		<b>CLOWES, A., et al.</b> "Suppression of Heparin of Smooth Muscle Cell Proliferation in Injured Arteries", Nature Vol. 265 pp. 25-26 (1977)	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov). <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. <sup>6</sup> If possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 12

Confirmation Number	7706
Application Number	10/813,965
Filing Date	March 31, 2004
First Named Inventor	Robert Falotico
Group Art Unit	1628
Examiner Name	Jennifer M. Kim
Attorney Docket Number	CRD5073USNP

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		<b>COLBURN</b> , M, et al. "Dose Responsive Suppression of Myointimal Hyperplasia by Dexamethasone", J. Vascular Surgery, Vol. 15 pp. 510-518 (1992)	
		<b>CURRIER</b> , J., et al. "Restenosis After Percutaneous Transluminal Coronary Angioplasty: Have We Been Aiming at the Wrong Target?" JACC, Vol. 25, No. 2, pp. 516-520 (1995)	
		<b>CURRIER</b> , J., et al. "Colchicine Inhibits Restenosis After Iliac Angioplasty in the Atherosclerotic Rabbit", Circulation 80, No. 4, pp. 11-66 (1989)	
		<b>DEROANNE</b> , C., et al. "Histone Deacetylases Inhibitors as Anti-Angiogenic Agents Altering Vascular Endothelial Growth Factor Signaling", Oncogene (2002) Vol. 21, pp. 427-436	
		<b>EDELMAN</b> , E., et al. "Pathobiologic Responses to Stenting", American Journal of Cardiology, Vol. 81, Issue 7, Suppl. 1 (April 1998) pp. 4E-6E	
		<b>FARB</b> , A., et al. "Vascular Smooth Muscle Cell Cytotoxicity and Sustained Inhibition of Neointimal Formation by Fibroblast Growth Factor 2-Saporin Fusion Protein", Circulation Research Vol. 80(4) pp. 542-550 (1997)	
		<b>FERNS</b> , G., et al. "Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF", Reports p. 1129-1132 (1991)	
		<b>FERNS</b> , G., et al. "Probucol Inhibits Neointimal Thickening and Macrophage Accumulation After Balloon Injury in the Cholesterol-Fed Rabbit", Proc. National Academy Science, Vol. 89, pp. 11312-11316 (1992)	
		<b>FLEISCHMAN</b> , L., et al. "Ras-Transformed Cells: Altered Levels of Phosphatidylinositol-4,5-Bisphosphate and Catabolite", Reports (1986) pp. 407-410	
		<b>FRANKE</b> , T. et al. "P13K: Downstream AKTion Blocks Apoptosis", Cell. Vol. 88, pp. 435-437 (1997)	
		<b>FUKUYAMA</b> , J., et al. "Tranilast Suppresses Intimal Hyperplasia After Balloon Injury In Rabbits Fed On a high-Cholesterol Diet", European Journal of Pharmacology, Vol. 318 pp. 327-332 (1996)	
		<b>GALIS</b> , Z., et al. "Cytokine-Stimulated Human Vascular Smooth Muscle Cells Synthesize a Complement of Enzymes Required for Extracellular Matrix Digestion", Circulation Research Vol. 75 pp. 181-189 (1994)	
		<b>GEORG</b> , G., et al. "Synthesis of Biologically Active Taxol Analogues with Modified Phenylisoserine Side", J. Medical Chemistry, Vol. 35 pp. 4230-4237 (1992)	
		<b>GIMON</b> , M., et al. "Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry of Paclitaxel and Related Taxanes", Journal of Natural Products, Vol. 57(1) pp. 1404-1410 (1994)	
		<b>GUIETTE-VOEGELEIN</b> , F., et al. "Relationships Between The Structure of Taxol Analogues and Their Antimitotic Activity", J. Medical Chemistry, Vol. 34 pp.992-998 (1991)	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov). <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. <sup>6</sup> If possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 12

Confirmation Number	7706
Application Number	10/813,965
Filing Date	March 31, 2004
First Named Inventor	Robert Falotico
Group Art Unit	1628
Examiner Name	Jennifer M. Kim
Attorney Docket Number	CRD5073USNP

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		<b>GUYTON, J.</b> , et al. "Inhibition of Rat Arterial Smooth Muscle Cell Proliferation by Heparin", Circulation Research, Vol. 46(5) pp. 625-634 (1980)	
		<b>HAAS-KOGAN, D.</b> , et al. "Protein Kinase B (PKB/akt) Activity is Elevated in Glioblastoma Cells Due to Mutation of the Tumor Suppressor PTEN/MMAC", Current Biology, Vol. 8(21) pp. 1195-1198 (1998)	
		<b>HANSSON, G.</b> , et al. "Interferon-Gamma Inhibits Arterial Stenosis After Injury", Circulation 84 pp. 1266-1272 (1991)	
		<b>HANSON, S.</b> , et al. "Interruption of Acute Platelet-Dependent Thrombosis by the Synthetic Antithrombin D-Penylalanyl-propyl-arginyl chloromethyl Ketone", Proc. Nat. Academy of Science, Vol. 85 pp. 3184-3188 (1988)	
		<b>HOLTON, R.</b> , et al. "A Synthesis of Taxusin", J. American Chemical Society, Vol. 110 No. 19 pp. 6558-6560 (1988)	
		<b>IKADA, Y.</b> , et al. "Sterocomplex Formulation Between Enantiomeric Poly(lacides)", Macromolecules 20 pp. 904-906 (1987)	
		<b>JONASSON, L.</b> , et al. "Cyclosporin A Inhibits Smooth Muscle Proliferation in the Vascular Response to Injury", Proc. Natl. Acad. Sci (USA) Vol. 85 (April 1988) pp. 2303-2306	
		<b>KU, G.</b> , "Inhibition by Probucol of Interleukin 1 Secretion and Its implication in Atherosclerosis", American J. Cardiology Vol. 62 pp. 77B-81B (1988)	
		<b>KUGIYAMA, K.</b> , et al. "Impairment of Endothelium-Dependent Arterial Relaxation by Lysolecithin in Modified Low-Density Lipoproteins", Nature, Vol. 344 pp. 160-162	
		<b>KUNISHIMA, T.</b> , et al. "A Randomized Trial of Aspirin Versus Cilostazol Therapy After Successful Coronary Stent Implantation", Clinical Therapeutics, Vol. 19(5) pp. 1058-1066 (1997)	
		<b>KUZUYA, M.</b> , et al. "Probucol Prevents Oxidative Injury to Endothelial Cells", Journal of Lipid Research, Vol. 32 pp. 197-204 (1991)	
		<b>LANG, R.</b> , et al. "Effects of Okadaic Acid and ATPyS on Cell Length and CA <sup>2+</sup> Channel Currents Recorded in Single Smooth Muscle Cells of the Guinea-pig Taenia Caeci", British J. pharmacol. (1991) pp. 331-336	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov). <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 12

Confirmation Number	7706
Application Number	10/813,965
Filing Date	March 31, 2004
First Named Inventor	Robert Falotico
Group Art Unit	1628
Examiner Name	Jennifer M. Kim
Attorney Docket Number	CRD5073USNP

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		<b>LANGILLE, B., et al.</b> "Reductions in Arterial Diameter Produced by Chronic Decreases in Blood Flow Are Endothelium-Dependent", Reports, Science, Vol. 231 pp. 405-407 (1986)	
		<b>LEE, Y., et al.</b> "Effectiveness of Probucol in Preventing Restenosis After Percutaneous Transluminal Coronary Angioplasty", Japan Heart J. pp. 327-332 (1996)	
		<b>Circulation:</b> LEE 84: 11-299 Abstracts From the 64th Scientific Sessions (1991)	
		<b>LEIBEL, S. et al.</b> "Radiation Therapy for Neoplasms of the Brain", J. Neurosurgery Vol. 66 pp. 1-22 (1987)	
		<b>LIU, M., et al.</b> "Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit", Circulation 81, No. 3 pp. 1089-1093 (1990)	
		<b>LONG, B., et al.</b> "Pacitaxel Inhibits Progression of Mitotic Cells to G Phase by Interference With Spindle Formation Without Affecting Another Microbubble Functions During Anaphase and Telephase", Cancer Research Vol. 54 pp. 4355-4361 (1994)	
		<b>LUNDERGAN, C., et al.</b> "Peptide Inhibition of Myointimal Proliferation by Angiopeptin, A Somatostatin Analogue", JACC, Vol. 17(6) pp. 132B-6B (1991)	
		<b>MAJESKY, M., et al.</b> "Heparin Regulates Smooth Muscle S Phase Entry in the Injured Rat Carotid Artery", Circulation Research, Vol. 61(2) p. 296-300 (1987)	
		<b>MARX, S., et al.</b> "Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells", Circulation Research Vol. 76(3) pp. 412-417 (1995)	
		<b>MINTZ, G., et al.</b> "Limitations of Angiography in the Assessment of Plaque Distribution in Coronary Artery Disease", Circulation, Vol. 93 pp. 924-932 (1996)	
		<b>MINTZ, G., et al.</b> "Arterial Remodeling After Coronary Angioplasty: A Serial Intravascular Ultrasound Study", Circulation, Vol. 94(1) pp. 35-43 (1996)	
		<b>MINTZ, G., et al.</b> "Intravascular Ultrasound Predictors of Restenosis After Percutaneous Transcatheter Coronary Revascularization", JACC, Vol. 27(7) p. 1678 (1996)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov). <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. <sup>6</sup> if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) Sheet 10 of 12	<b>Confirmation Number</b>	7706
	<b>Application Number</b>	10/813,965
	<b>Filing Date</b>	March 31, 2004
	<b>First Named Inventor</b>	Robert Falotico
	<b>Group Art Unit</b>	1628
	<b>Examiner Name</b>	Jennifer M. Kim
	<b>Attorney Docket Number</b>	CRD5073USNP

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Exam Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		<b>MORENA, H., et al.</b> "Comparison of the Effects of Regional Ischemia, Hypoxia, Hyperkalemia, and Acidosis on Intracellular and Extracellular Potentials and Metabolism in the Isolated Porcine Heart", Circulation Research, Vol. 46(5) p. 634 (1980)	
		<b>NEMECEK, G., et al.</b> "Terbinaine Inhibits the Mitogenic Response to Platelet-Derived Growth Factor in Vitro and Neointimal Proliferation in Vivo", Journal of Pharmacology and Experimental Therapeutics, Vol. 245(3) pp. 1167-1174	
		<b>NUNES, G.,</b> "Combination of Vitamins C and E Alters the Response to Coronary Balloon Injury in the Pig", Arterioscler. Thromb and Vascular Biol. Vol. 15(1) pp. 156-165 (1995)	
		<b>OKADA, T., et al.</b> "Localized Release of Perivascular Heparin Inhibits Intimal Proliferation After Endothelial Injury Without Systemic Anticoagulation", Neurosurgery(1989), Vol. 25(6), pp. 892-898	
		<b>ORGILL, D., et al.</b> "Current Concepts and Approaches to Wound Healing", Critical Care Medicine, Vol. 15(9) pp. 899-908 (1988)	
		<b>OZAKI, H., et al.</b> "Calcium-Independent Phosphorylation of Smooth Muscle Myosin Light Chain by Okadaic Acid Isolated From Black Sponge", Journal of Pharmacology and Experimental Therapeutics, Vol. 243(3) pp. 1167-1173 (1987)	
		<b>PARTHASARATHY, S., et al.</b> "Probucol Inhibits Oxidative Modification of Low Density Lipoprotein", J. Clinical Investigation, Vol. 77 pp. 641-644 (1986)	
		<b>PAZDUR, R., et al.</b> "The Taxoids" Paclitaxel (Taxol) and Docetaxel (Taxotere)" Cancer Treatment Reviews, Vol. 19 pp. 351-386 (1993)	
		<b>POWELL, J.</b> "Inhibitors of Angiogenesis-Converting Enzyme Prevents Myointimal Proliferation After Vascular Injury" Science, Vol. 245 (186-188 (1989)	
		<b>POZZATI, E.,</b> "The Growth of Cerebral Cavernous Angiomas", Neurosurgery, Vol. 25(10) pp. 92-97 (1989)	
		<b>PULCANI, J., et al.</b> "Preparation of 7-Modified Docetaxel Analogs Using Electrochemistry", Tetrahedron Letters, Vol. 35(52) p. 9709-9712 (1994)	
		<b>RAJAGOPALAN, S., et al.</b> "Reactive Oxygen Species Produced by Macrophage-Derived Foam Cells Regulate the Activity of Vascular Matrix Metalloproteinases in Vitro", J. Clinical Investigation, Vol. 98(11) pp. 2572-2579 (1996)	
		<b>REISER, K., et al.</b> "Enzymatic and Nonenzymatic Cross-Linking of Collagen and Elastin", The FASAB Journal, Vol. 6 pp. 2439-2449 (1992)	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov). <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) Sheet 11 of 12	<b>Confirmation Number</b>	7706
	<b>Application Number</b>	10/813,965
	<b>Filing Date</b>	March 31, 2004
	<b>First Named Inventor</b>	Robert Falotico
	<b>Group Art Unit</b>	1628
	<b>Examiner Name</b>	Jennifer M. Kim
	<b>Attorney Docket Number</b>	CRD5073USNP

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Exam Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		<b>RINGEL, I., et al. "Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol", J. National Cancer Institute, Vol. 83(4) pp. 288-291 (1991)</b>	
		<b>SAITO, N., et al. "Intramedullary Cavernous Angioma With Trigeminal Neuralgia: A Case Report and Review of the Literature", Neurosurgery pp. 97-101 (1989)</b>	
		<b>SCHIFF, P., et al. "Promotion of Microbutule Assembly in Vitro by Taxol", Nature, Vol. 277 p. 665-667 (1979)</b>	
		<b>SCHNEIDER, J., et al. "Probucol Deceases Neointimal Formation in a Swine Model of Coronary Artery Balloon Injury", Circulation, Vol. 88 pp. 628-637 (1993)</b>	
		<b>SCULLY, R., et al. "Case Records of the Massachusetts General Hospital", The New England Journal of Medicine p. 924 (1989)</b>	
		<b>SERRUYS, P., et al. "Heparin-Coated Palmaz-Schartz Stents in Human Coronary Arteries: Early Outcome of the Benestent-II Pilot Study", Circulation Volume 93(3) pp. 412-422 (1996)</b>	
		<b>SETSUDA, M., et al. "Probucol Therapy in the Prevention of Restenos After Successful Percutaneous Transluminal Coronary Angioplasty", Clinical Therapeutics, Vol. 15(2) pp. 374-382 (1993)</b>	
		<b>SHAYESTEH, L., et al. "PIK3CA is Implicated as an Oncogene in Ovarian Cancer", Nature Genetics, Vol. 21 pp. 99-102 (1999)</b>	
		<b>SIDDIQUI, M., et al. "Isolation and Sequencing of a cDNA Coding for the Human DF3 Breast Carcinoma-Associated Antigen", Proc. National Academy of Science, Vol. 85 pp. 2320-2323 (1989)</b>	
		<b>SIMONS, M., et al. "Antisense c-myb Oligonucleotides Inhibit Intimal Arterial Sooth Muscle Cell Accumulation in Vivo", Nature, Vol. 359 pp. 67-70 (1992)</b>	
		<b>SNOW, A., et al. "Heparin Modulates the Composition of the Extracellular Matrix Domain Surrounding Arterial Smooth Muscle Cells", American Journal of Pathology, Vol. 73(2) pp. 313-330 (1990)</b>	
		<b>SOLLOTT, S., et al. "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation After Angioplasty in the Rat", the Journal of Clinical Investigation, Vol. 95 pp. 1869-1876 (1995)</b>	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov). <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 12 of 12

<i>Confirmation Number</i>	7706
<i>Application Number</i>	10/813,965
<i>Filing Date</i>	March 31, 2004
<i>First Named Inventor</i>	Robert Falotico
<i>Group Art Unit</i>	1628
<i>Examiner Name</i>	Jennifer M. Kim
<i>Attorney Docket Number</i>	CRD5073USNP

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Exam Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		<b>SOUTHGATE, K.</b> , et al. "Involvement of Extracellular-Matrix-Degrading Metalloproteinases in Rabbit Aortic Smooth-Muscle Cell Proliferation" <i>Biochem. J.</i> Vol. 288 pp. 93-99 (1992)	
		<b>SOUTHHORN, P.</b> , et al. "Free Radicals in Medicine: Chemical Nature and Biologic Reaction", <i>Mayo Clin. Proc.</i> Vol. 63 pp. 381-389 (1988)	
		<b>STEINBERG, D.</b> , "Studies on the Mechanism of Action of Probucol", <i>American J. Cardiology</i> , Vol. 57p. 16H-21H (1986)	
		<b>STIERLE, A.</b> , et al. "Taxol and Taxane Production by <i>Taxomyces Andreanae</i> , An Endophytic Fungus of Pacific Yew", <i>Science</i> , Vol. 260 pp. 214-216 (1993)	
		<b>STRAUSS, B.</b> , et al. "Extracellular Matrix Remodeling After Balloon Angioplasty Injury in a Rabbit Model of Restenosis" <i>Circulation Research</i> , Vol. 75 pp. 650-658 (1994)	
		<b>TAKE, S.</b> , et al. "Effect of Cilostazol in Preventing Restenosis After Percutaneous Transluminal Coronary Angioplasty", <i>American J. of Cardiology</i> , Vol. 79 pp. 1097-1099 (1997)	
		<b>TANAKA, H.</b> , et al., "Sustained Activation of Vascular Cells and Leukocytes in the Rabbit Aorta After Balloon Injury", <i>Circulation</i> , Vol. 88, pp. 1788-1803 (1993)	
		<b>TSUCHIKANE, E.</b> , et al. "Impact of Cilostazol in Restenosis After Percutaneous Coronary Balloon Angioplasty", <i>Circulation</i> , pp. 21-26 (1999)	
		<b>WANI, M.</b> , et al. "Plant Anti-Tumor Agents, VI. The Isolation and Structure of Taxol, a Novel Antileukemic and Antitumor Agent from <i>Taxus Brevifolia</i> ", <i>J. Am. Chem. Soc.</i> (1971) Vol. 93 pp. 2325-2327	
		<b>WATANABWE, K.</b> , et al. "Preventive Effects of Probucol on Restenosis After Percutaneous Transluminal Coronary Angioplasty", <i>American Heart Journal</i> , Vol. 132 No. 1, Part 1 pp. 23-29 (1996)	
		<b>WEINBERGER, J.</b> , et al. "Intracoronary Irradiation; Dose Response for the Prevention of Restenosis in Swine", <i>International J. Radiation Oncology Biol. Phys.</i> Vol. 36(4) pp. 767-775 (1996)	
		<b>WILEY and SONS</b> , Chapter 2: "Modern Fluoropolymers - High Performance Polymers for Diverse Applications", pp. 71-90 (1997)	
		<b>WOO, S.</b> , et al. "Structurally Simple Trichostatin A-Like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors", <i>J. Med. Chemistry</i> (2002) Vol. 45, pp. 2877-2885	
		<b>ZHANG, S.</b> , et al. "A New 11(1 1)-Abeo-Taxane from <i>Taxus Yunnanensis</i> ," <i>Journal of Natural Products</i> , Vol. 57(11) pp. 1580-1583 (1994)	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov). <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.